Abstract
Juvenile xanthogranuloma (JXG) is an uncommon non-Langerhans cell histiocytic disorder that occurs predominantly in infants. Traditional treatment of ocular JXG involves the administration of topical or local corticosteroids. We treated 2 children with JXG refractory to local corticosteroid therapy with off-label intraocular bevacizumab. To our knowledge, this is the first report of successful use of bevacizumab for ocular JXG.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 295-297 |
| Number of pages | 3 |
| Journal | Journal of AAPOS |
| Volume | 18 |
| Issue number | 3 |
| DOIs | |
| State | Published - Jun 2014 |
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Ophthalmology
Fingerprint
Dive into the research topics of 'Successful treatment of juvenile xanthogranuloma using bevacizumab'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS